<subsec_element><subsec_header></subsec_header><slide_intro></slide_intro><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide1.png</sec_img><sec_label>Slide 1.</sec_label><sec_caption></sec_caption><sec_txt><h3> Biotherapeutics: Understanding Immunogenicity for Clinical Practice</h3></sec_txt><sec_alt_txt>Slide 1.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide2.png</sec_img><sec_label>Slide 2.</sec_label><sec_caption></sec_caption><sec_txt><h3> Faculty</h3></sec_txt><sec_alt_txt>Slide 2.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide3.png</sec_img><sec_label>Slide 3.</sec_label><sec_caption></sec_caption><sec_txt><h3> Introduction<sup type="ref">[1-5]</sup></h3></sec_txt><sec_alt_txt>Slide 3.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide4.png</sec_img><sec_label>Slide 4.</sec_label><sec_caption></sec_caption><sec_txt><h3> Program Outline</h3></sec_txt><sec_alt_txt>Slide 4.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide5.png</sec_img><sec_label>Slide 5.</sec_label><sec_caption></sec_caption><sec_txt>
SOME STUFF

</sec_txt><sec_alt_txt>Slide 5.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide6.png</sec_img><sec_label>Slide 6.</sec_label><sec_caption></sec_caption><sec_txt><h3> Impact of ADAs<sup type="ref">[6]</sup></h3><li>	The clinical potential of ADAs is primarily within the pharmacokinetics (PK) of the biologic agent</li><li>	What is relevant is that some patients make only a few molecules/antibodies against the therapeutic agent, resulting is a substantial amount of free drug to be available</li><li>	In other patients, a large amount of molecules/antibodies are made against the drug complex, resulting in very little effect of the drug; the remaining active concentration may become zero</li><li>	However, the bottom line is that if there is sufficient drug concentration to obtain the desired therapeutic effect, then the level of immunogenicity that occurs is not relevant</li><li>	Injection site reactions do occur, but they are usually not mediated by ADAs</li></sec_txt><sec_alt_txt>Slide 6.</sec_alt_txt><qna_form></qna_form></slide_grp><qna_form></qna_form></subsec_element>